On Thursday 2 December, the European Medicines Agency (EMA) announced that it had begun a rolling review of French pharmaceutical company Valneva’s vaccine candidate, VLA2001.
This is an inactivated vaccine and therefore contains a “killed” form of SARS-CoV-2 and two adjuvants that enhance the immune response to the vaccine.
“When a person is given the vaccine, their immune system identifies the inactivated virus as foreign and makes antibodies against it. If, later, the vaccinated...